State Street Corp Takes Position in Longeveron Inc. (NASDAQ:LGVN)

State Street Corp bought a new position in Longeveron Inc. (NASDAQ:LGVN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,180 shares of the company’s stock, valued at approximately $29,000. State Street Corp owned about 0.11% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Renaissance Technologies LLC acquired a new position in shares of Longeveron in the 2nd quarter valued at $236,000. 10.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LGVN shares. Roth Capital upgraded Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm started coverage on Longeveron in a report on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Longeveron in a report on Monday, November 25th.

Longeveron Price Performance

Shares of LGVN opened at $1.91 on Friday. Longeveron Inc. has a 12 month low of $0.77 and a 12 month high of $13.50. The stock’s 50-day moving average is $1.96 and its two-hundred day moving average is $2.22. The stock has a market cap of $28.34 million, a PE ratio of -0.30 and a beta of 0.31.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.19. Longeveron had a negative return on equity of 142.43% and a negative net margin of 967.49%. The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.34 million. During the same period in the previous year, the company posted ($2.80) EPS. On average, research analysts anticipate that Longeveron Inc. will post -3.69 earnings per share for the current year.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.